Clec11a, also known as stem cell growth factor (SCGF), C-type lectin superfamily member 3 (CLECSF3), or osteolectin, is a sulfated glycoprotein. It significantly promotes the osteogenic differentiation of bone marrow mesenchymal stem cells and osteoblasts, stimulates chondrocyte proliferation, and is involved in the stress/adaptive response of bone to exercise via mechanical stimulation of the cation channel Pieoz1. It also plays a role in regulating hematopoietic differentiation and homeostasis [2,3].

In osteoporosis mouse models, human umbilical cord mesenchymal stromal cell-derived extracellular vesicles (hucMSC-EVs) prevent bone loss and maintain bone strength by enhancing bone formation, reducing marrow fat accumulation, and decreasing bone resorption. This is achieved through CLEC11A-mediated regulation of bone metabolism. Specifically, CLEC11A in hucMSC-EVs enhances the shift from adipogenic to osteogenic differentiation of bone marrow mesenchymal stromal cells (BMSCs) and inhibits osteoclast formation [1].

In summary, Clec11a is crucial for bone health, playing key roles in bone construction, remodeling, and metabolism. Its study, especially through models like those involving hucMSC-EVs in osteoporosis, provides insights into potential therapeutic strategies for bone diseases [1,2].